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Platelet inhibition limits TGF-b overexpression and matrix
expansion after induction of anti-thy1 glomerulonephritis
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Platelet inhibition limits TGF-b overexpression and matrix ex-
pansion after induction of anti-thy1 glomerulonephritis.
Background. Although a role of platelets is well established
in atherosclerosis, only little is known about their contribution
to pathologic renal matrix expansion. The present study ana-
lyzes the effect of the platelet inhibitor clopidogrel on the early
injury and subsequent repair phase of experimental anti-thy1
glomerulonephritis.
Methods. In male Sprague-Dawley rats, acute anti-thy1
glomerulonephritis was induced by intravenous injection of
OX-7 antibody. In protocol 1 (injury), clopidogrel was given
starting 5 days before antibody injection. One day after disease
induction, parameters of mesangial cell injury (glomerular cell
number, inducible NO synthesis, and macrophage infiltration)
were analyzed. In protocol 2 (repair), clopidogrel treatment
was started one day after antibody injection. On day 6, param-
eters of glomerular repair [glomerular matrix score, expression
of transforming growth factor (TGF)-b1, fibronectin, and plas-
minogen activator inhibitor (PAI)-1] and thrombosis (aneurysm
formation and fibrinogen deposition) were determined. In both
protocols, an additional group of rats was treated with the
angiotensin-converting enzyme (ACE) inhibitor enalapril.
Results. In the injury protocol, platelet inhibition did not
affect mesangial cell lysis, glomerular NO production, and
macrophage infiltration, while ACE inhibition was protec-
tive. In the repair protocol, clopidogrel significantly limited
aneurysm formation and fibrinogen deposition, as well as
glomerular matrix expansion, TGF-b1, fibronectin, and PAI-
1 expression. In comparison, enalapril was less effective in
preventing glomerular thrombosis, but was significantly supe-
rior to clopidogrel in limiting matrix protein expression and
accumulation.
Conclusion. The present study shows that platelets play a sig-
nificant role in the sequence from mesangial cell injury to renal
matrix expansion in anti-thy1 glomerulonephritis. The results,
directly comparing renin-angiotensin-system and platelet inhi-
bition, suggest that platelets contribute less than angiotensin
II to TGF-b overexpression and matrix accumulation in this
model of acute glomerular wound repair.
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Overexpression of the cytokine transforming growth
factor (TGF)-b and expansion of extracellular matrix
are key elements of a highly orchestrated molecular and
cellular program called wound repair [1, 2]. Among dif-
ferent organs and systems, wound repair is a relatively
uniform response to various forms of tissue injury that
derive from inflammation, hypoxia, diabetes, or hyper-
tension [1, 3]. Numerous molecular factors involved in
tissue injury have been shown to directly induce TGF-b
overexpression [4, 5]. These factors include immune com-
plexes, free radicals, chemokines, high glucose levels, ad-
vanced glycosylated end products, ischemia, mesangial
cell stretch, protein trafficking, basic fibroblast growth
factor, and TGF-b itself. TGF-b is unique in its ability to
promote matrix accumulation by simultaneously increas-
ing synthesis of matrix proteins, decreasing degradation
of matrix proteins, and increasing expression of cell ma-
trix receptors called integrins [1, 2]. The key role of TGF-
b in acute and chronic tissue repair has been highlighted
by experimental studies demonstrating that specific an-
tagonism of TGF-b largely prevents matrix expansion
in both acute and chronic fibrotic disease of the kidney
[6, 7].
As is the case for other tissues, matrix expansion in the
glomerulus is a temporally and spatially highly coordi-
nated process, and closely directed toward the site where
the initial injury has occurred. This orchestration involves
a well-ordered change in the gene expression of resident
glomerular cells, such as mesangial cells, podocytes, and
endothelial cells, as well as a coordinated glomerular lo-
calization of blood cells (i.e., macrophages, lymphocytes,
and platelets) to the site of action [1, 5, 8, 9]. While
in recent years major progress has been made in the
understanding of the molecular mechanism underlying
glomerular matrix expansion [1, 8], and more recently, of
the role of infiltrating macrophages [9], the contribution
of platelets to this process is less defined by far. This is in
contrast to tissue repair processes in other organs, such as
dermal wounding and both acute and chronic occlusive
vascular disease, in which a profibrotic role of platelets
has been well established [10, 11].
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In order to further characterize the role of platelets
in renal matrix expansion, we tested the effect of the
recently clinically introduced platelet inhibitor clopido-
grel on acute anti-thy1 glomerulonephritis, a rat model
of acute glomerular wound repair. Clopidogrel is struc-
turally a thienopyridine derivate and specifically inhibits
ADP-dependent platelet aggregation and adhesion via
inhibition of the purinergic P2Y12 receptor [12, 13], and,
unlike aspirin, has no additional effects on prostaglandin
metabolism and actions [14, 15]. In two separate pro-
tocols, actions of platelet inhibition on early, anti-thy1
antibody- and nitric oxide (NO)-mediated mesangial cell
injury, and subsequent TGF-b overexpression and ma-
trix accumulation were determined (day 1 and day 6 af-
ter antibody injection, respectively). In both protocols,
the effect of clopidogrel was compared side by side with
the ACE inhibitor enalapril.
METHODS
Materials
Unless otherwise indicated, materials, chemicals, or
culture media were purchased from Sigma Chemical-
Aldrich Co. (Taufkirchen, Germany).
Animals
Male Sprague-Dawley rats (180 to 250 g) obtained from
Charles River (Sulzfeld, Germany) were fed a normal
protein diet (22.5% protein, Altromin, Lage, Germany)
for at least three days before the start of the experiment
to allow equilibration. Body weight was determined at
the beginning and end of each experiment. Food and wa-
ter intake were monitored. Animal care and treatment
were in conformity with the guidelines of the American
Physiological Society and approved by local authorities.
Animals were housed in a constant temperature room
with a 12-hour dark/12-hour light cycle.
Induction of acute anti-thy1 glomerulonephritis
Acute anti-thy1 glomerulonephritis was induced by tail
vein injection of the monoclonal antibody OX-7 [1 mg/kg
body weight in phosphate-buffered saline (PBS)] as pre-
viously described [16]. In the kidney, OX-7 binds to a
thy1-like antigen on the surface of mesangial cells and
causes complement- and NO-dependent cell lysis [17].
Control animals were injected with equal volumes of PBS
only. OX-7 antibody was produced from a hybridoma cell
line as previously described [16]. The antibodies were di-
luted in PBS (pH 7.4) and stored at −70◦C until use.
Drug administration
Both clopidogrel and enalapril were given with food.
The drug-containing food was produced in our labora-
tory by using the flour of the standard rat chow (22.5%
protein, A1311, Altromin). Clopidogrel or enalapril was
mixed into the dry food flour in appropriate amounts,
water was added to form pellets, and the air-dried pellets
were subsequently given to the animals.
Clopidogrel, chemically the hydrogen sulfate salt of
the S enantiomer of methly [2(2-chlorophenyl)-2[4,5,6,7-
tretarhydrothieno(3,4-c)pyridine-5-yl]acetate, was given
in a daily dose of 10 mg/kg body weight. This dose has
previously been reported to maximally inhibit platelet
aggregation and thrombus formation in vitro and in vivo
[18]. The ACE inhibitor enalapril was used in a dose
of 50 mg/kg body weight. In previous studies, this dose
was maximally effective in reducing TGF-b overexpres-
sion during the repair phase of acute anti-thy1 glomeru-
lonephritis [16].
Experimental design
In the model of acute anti-thy1 glomerulonephritis,
the effects of the platelet inhibitor clopidogrel and the
ACE inhibitor enalapril were determined separately on
early mesangial cell lysis (injury phase, day 1, proto-
col 1) and on the subsequent TGF-b1 overexpression
and matrix accumulation (matrix expansion phase, day
6, protocol 2). In protocol 1 (injury), treatment was
started five days before and continued until 24 hours after
injection of anti-thy1 antibody. Here, glomerular cell
number and inducible NO production were analyzed as
estimates of mesangial cell injury. In protocol 2 (repair),
treatment was started one day after and continued until
day 6 after antibody administration. On day 6, parame-
ters of glomerular repair (glomerular matrix score and
expression of TGF-b1, fibronectin, and PAI-1 protein)
were determined.
Protocol 1
Effect on the injury phase of acute anti-thy1 glomeru-
lonephritis (day 1 after antibody injection). Five days
before antibody injection, Sprague-Dawley rats were
assigned to the following groups: (1) PBS-injected
control animals (N = 4, control); (2) anti-thy1 antibody-
injected animals, no treatment (GN, N = 8); (3) anti-thy1
antibody-injected rats plus clopidogrel (GN + Clopi, N =
7); and (4) anti-thy1 antibody-injected rats plus enalapril
(GN + Ena, N = 8).
One day after antibody injection, the histologic de-
gree of mesangial cell lysis, the release of basal and
LPS-stimulated nitrite of cultured glomeruli, and
glomerular macrophage infiltration were analyzed. At
this point, mesangial cell lysis is complete and inducible
glomerular NO production is markedly increased [19].
Previous investigations in anti-thy1 glomerulonephritis
have shown that glomerular binding of the antibody is
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not affected by platelet inhibition or enalapril treatment
[20, 21].
Protocol 2
Effect on the repair phase of anti-thy1 glomerulonephri-
tis (day 6 after antibody injection). One day after anti-
body injection, when the mesangial cell lysis had occurred
and the fibrotic response had started [19], Sprague-
Dawley rats were assigned to the following groups:
(1) PBS-injected control animals (N = 4, control); (2)
anti-thy1 antibody-injected animals, no treatment (GN,
N = 8); (3) anti-thy1 antibody-injected rats plus clopido-
grel (GN + Clopi, N = 8); and (4) anti-thy1 antibody-
injected rats plus enalapril (GN + Ena, N = 8).
Six days after disease induction, expression of the key
fibrosis mediator and marker TGF-b served as princi-
pal therapeutic target. To document that TGF-b expres-
sion reflected actual matrix accumulation, a histologic
glomerular matrix score was used. In addition, renal ex-
pression of the matrix protein fibronectin was measured
as an indicator for matrix protein production. PAI-1 was
used as sensitive marker of the matrix degrading sys-
tem. In acute anti-thy1 glomerulonephritis, the fibrotic
response peaks 6 days after antibody injection and pro-
vides a large difference between normal and disease
levels [16]. In addition, signs of intraglomerular thrombo-
sis (aneurysm formation and fibrinogen deposition) were
determined histologically. In acute anti-thy1 glomeru-
lonephritis, glomerular aneurysms develop as a conse-
quence of mesangial cell lysis and subsequent capillary
ballooning and intracapillary thrombosis. Both glomeru-
lar fibrinogen deposition and aneurysm numbers were
used as indirect indices to show that potential antifibrotic
effects by clopidogrel are paralleled by less glomerular
platelet localization.
Bleeding time
Rat tail bleeding time was analyzed as previously re-
ported in anesthetized animals with a standardized inci-
sion (10 mm long, 1 mm deep) on the dorsal part of the
tail [22]. Bleeding time was determined exemplarily in 4
animals of each group of protocol 2 on day 5 after disease
induction.
Urine collection and measurement of albuminuria
In protocol 2, a 24-hour urine was collected from each
rat the day before sacrifice, using metabolic cages. Albu-
minuria was measured using a microplate technique and
a rabbit antirat albumin peroxidase-conjugated antibody
[23]. Albuminuria is expressed as mg protein/24 h.
Sacrifice
At the end of each experiment, animals were anes-
thetized with ether. Following a midline abdominal inci-
sion, 5 to 10 mL blood was drawn from the abdominal
aorta, and the kidneys were subsequently perfused with
20 mL ice-cold PBS. For histologic examination, cortical
tissue was fixed in 10% neutral buffered formalin.
Production of TGF-b1, fibronectin, and PAI-1
by glomeruli in culture
Glomeruli from individual rats were isolated by a
graded sieving technique (160-, 125-, and 71-lm mesh
metal sieves) as described previously [16]. Glomeruli
were suspended in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 0.1 U/mL insulin, 100 U/
mL penicillin, and 100 lg/mL streptomycin. For stim-
ulation of iNOS, 10-lg lipopolysaccharide (LPS) from
Escherichia coli (serotype 0127:B8) per mL was added.
Glomeruli were cultured at a density of 2000 per mL for
48 hours. In previous experiments, we have shown that the
TGF-b1, fibronectin, and PAI-1 production by glomeruli
ex vivo is constant over 48 hours and closely correlates the
actual glomerular matrix accumulation in vivo [24]. After
48 hours’ incubation at 37◦C/5% CO2, supernatants were
harvested and stored at −70◦C until analysis of TGF-b1,
fibronectin, PAI-1, or nitrite content.
Measurement of TGF-b1, fibronectin, and PAI-1
TGF-b1 content of culture supernatant was mea-
sured after acid activation using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (TGF-
b1 DuosetTM; R&D Systems, Wiesbaden, Germany) ac-
cording to the manufacturer’s instructions. Fibronectin
and PAI-1 levels were measured with modified inhibitory
ELISA according to published methods [16]. Three sam-
ples from each rat were analyzed.
Measurement of nitrite
Nitrite served as indicator of NO production, and was
determined by the Griess reaction in glomerular culture
supernatants [25]. Briefly, 100-lL of sample was mixed
with 100-lL Griess reagent (0.05% N-[1-naphthyl] ethy-
lene diamine dihydrochloride, 0.5% sulfanilamide in 45%
glacial acetic acid) in 96-well plates. After 10 minutes’ in-
cubation in the dark, absorbance was read at 546 nm in an
automated plate reader (MRX II; Dynex Technologies,
Frankfurt am Main, Germany). Standard samples were
prepared with sodium nitrite.
Glomerular iNOS mRNA expression
Glomerular total RNA was extracted by a guani-
dinium isothiocyanate method using TrizolTM reagent
(Gibco BRL, Berlin, Germany) according to the
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manufacturer’s instructions. iNOS mRNA expression
was determined by a standard relative reverse transcrip-
tion (RT)-polymerase chain reaction (PCR) method as
previously described [26]. The following primer pairs
were used: GAPDH: sense CCATCTTCCAGGAGC
GAGAT, antisense GATGACCTTGCCCACAGCCT
(24 cycles, 59◦C); iNOS: sense GCAGAATGTGACCAT
CATGG, antisense ACAACCTTGGTGTTGAAGGC
(34 cycles, 64◦C). PCR products were separated on a
2% agarose gel and analyzed by an imaging densito-
meter (Typhoon 8600; Amersham Pharmacia Biotech,
Buckinghamshire, UK). The density of the bands for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA was used as housekeeping gene. For quantitation
purposes, values of iNOS bands were divided by the band
density for GAPDH of the same sample.
Light and immunohistochemistry microscopy
All microscopic examinations were performed in a
blinded fashion. Three-lm sections of paraffin-embedded
tissue were stained with periodic-acid Schiff (PAS). In
protocol 1, the number of cell nuclei was counted in 20
glomeruli of 80 to 100 lm diameter from each animal for
calculation of mesangial cell lysis [19]. The number of in-
filtrating macrophages was analyzed in 20 glomeruli of
each animal using a primary mouse antibody (Serotec,
Hamburg, Germany) and a secondary goat antimouse
antibody coupled with the EnvisionTM staining system
(DakoCytomation, Hamburg, Germany). In protocol 2,
glomerular matrix expansion was evaluated on PAS-
stained slides by rating the percentage of mesangial ma-
trix occupying area in 20 glomeruli from each rat (0%
to 100%) [16]. Glomerular cell proliferation was ana-
lyzed using a primary mouse anti-proliferating cell nu-
clear antigen (PCNA) antibody (DakoCytomation) and
a secondary goat antimouse antibody coupled with the
EnvisionTM staining system (DakoCytomation). PCNA-
positive cells were counted in at least 15 glomeruli of each
animal. Furthermore, the percentage of aneurysmatic
glomeruli was calculated in at least 20 glomeruli of each
rat. Fibrinogen deposition was determined with a primary
rabbit antifibrinogen antibody and a secondary goat an-
tirabbit antibody coupled with the EnvisionTM staining
system (DakoCytomation). Glomerular fibrinogen de-
position is expressed as the percentage of fibrinogen-
positive area in 20 glomeruli from each rat (0% to
100%).
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM). Statistical analysis between the groups was
performed by one-way analysis of variance (ANOVA)
and subsequent t testing with Bonferroni correction for
multiple comparison. Data on mRNA expression were
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Fig. 1. Tail bleeding time in rats with induced anti-thy1 glomeru-
lonephritis (GN). Shown are the effects of the platelet inhibitor
clopidogrel (+Clopi) and the angiotensin-converting enzyme (ACE)
inhibitor enalapril (+Ena). Normal control animals (Control) were in-
jected with phosphate-buffered saline (PBS). Bleeding was induced by
a standard insertion (10 mm long and 1 mm deep) in anesthetized ani-
mals. ∗∗∗P < 0.001 vs. aGN.
analyzed by Mann-Whitney U test. A P value < 0.05 was
considered significant.
RESULTS
Body weight and bleeding time
In protocols 1 and 2, there were no significant differ-
ences in body weight at the beginning and at the end
of the experiment. Rat tail bleeding time was compara-
ble in normal and disease control rats (146 ± 9 sec and
173 ± 14 sec, P = NS) (Fig. 1). Treatment with clopido-
grel prolonged bleeding time as expected (683 ± 37 sec,
P < 0.001), while enalapril was without a significant ef-
fect (136 ± 15 sec, NS vs. control or GN). The increased
bleeding time caused by clopidogrel documents the in
vivo bioavailability of the drug.
Protocol 1
Effect on the injury phase of acute anti-thy1 glomeru-
lonephritis. Compared with the normal control animals,
injection of anti-thy1 antibody resulted in a significantly
reduced glomerular cell number (56.5 ± 1.4 vs. 43.0 ± 1.2,
P < 0.001) (Fig. 2) basal (0.8 ± 0.1 vs. 4.1 ± 0.7 nmol/mL,
P < 0.001) (Fig. 3A) and LPS-stimulated glomerular NO
production (2.9 ± 0.7 vs. 37.7 ± 5.0 nmol/mL, P < 0.001)
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Fig. 2. Glomerular cell number indicating mesangial cell lysis in rats
1 day after induction of acute anti-thy1 glomerulonephritis (GN) (pro-
tocol 1, injury). Depicted are the effects of clopidogrel (+Clopi) and
enalapril (+Ena). Normal control animals (Control) were injected with
phosphate-buffered saline (PBS). ∗P < 0.05 vs. aGN.
(Fig. 3B), and iNOS mRNA expression (14 ± 4% vs.
100%, P < 0.001) (Fig. 3C and D). Treatment with clopi-
dogrel had no significant influence on these parameters
(glomerular cell number: 42.9 ± 1.2; basal NO produc-
tion: 4.7 ± 1.1 nmol/mL; LPS-stimulated NO produc-
tion 37.4 ± 5.8 nmol/mL; and iNOS mRNA expression
104 ± 15%, P = NS for all parameters). In contrast,
administration of the ACE inhibitor enalapril signifi-
cantly reduced mesangial cell lysis (glomerular cell num-
ber: 47.6 ± 1.3, P < 0.05 vs. GN), basal NO production
(1.1 ± 0.4 nmol/mL, P < 0.001 vs. GN), LPS-stimulated
NO production (23.7 ± 3.1 nmol/mL, P < 0.05 vs. aGN),
and iNOS mRNA expression (63 ± 5%, P < 0.001
vs. GN). Because macrophages have been described as
an important source of glomerular iNOS expression in
anti-thy1 glomerulonephritis, the number of infiltrating
macrophages was determined 24 hours after disease
induction (Fig. 4). Compared with the normal con-
trol animals (0.21 ± 0.03), injection of anti-thy1 anti-
body resulted in a marked increase in the glomerular
macrophage number (3.1 ± 0.2). While clopidogrel did
not affect glomerular macrophage infiltration (3.0 ± 0.2),
the number of positive cells was significantly reduced
in the animals treated with enalapril (2.4 ± 0.1, P <
0.01).
Together, the results from protocol 1 consistently show
that platelet inhibition does not affect early mesangial cell
injury in acute anti-thy1 glomerulonephritis, while ACE
inhibition significantly limits macrophage infiltration, in-
duction of inducible NO production, and mesangial cell
lysis.
Protocol 2
Effect on the repair phase of acute anti-thy1 glomeru-
lonephritis. Six days after injection of anti-thy1 an-
tibody, disease was characterized by a significant
increase in albuminuria (95.2 ± 24.2 mg/24 h) (Fig. 5A),
glomerular cell proliferation (9.6 ± 0.5 PCNA-positive
cells/glomerular cross-section) (Fig. 5B), histologic
matrix accumulation (matrix score 78 ± 1.5%), and
glomerular production of TGF-b1 (1136 ± 102 pg/mL), fi-
bronectin (16915 ± 1869 ng/mL), and PAI-1 (435 ± 19 ng/
mL, P < 0.001 vs. control for all parameters) (Fig. 6A-
D). In addition, a marked increase in the percentage of
aneurysmatic glomeruli (20.0 ± 3.8%) and in the rela-
tive glomerular fibrinogen deposition (13.5 ± 2.4%) was
observed on day 6 (Fig. 7).
Treatment with clopidogrel decreased albuminuria
(51.3 ± 15.9 mg/24 h) (Fig. 5A) and significantly re-
duced glomerular cell proliferation (6.9 ± 0.8 PCNA-
positive cells/glomerular cross-section). Furthermore,
clopidogrel administration significantly decreased histol-
ogy matrix accumulation (matrix score 68.7 ± 3.0%) and
glomerular production of TGF-b1 (797 ± 71 pg/mL), fi-
bronectin (12285 ± 1419 ng/mL), and PAI-1 (239 ± 36 ng/
mL, P < 0.05 vs. GN for all parameters) (Fig. 6A-D).
Compared to clopidogrel, enalapril therapy was more ef-
fective in reducing albuminuria (26.0 ± 14.2 mg/24 h)
(Fig. 5), histologic matrix accumulation (matrix score 58.2
± 2.7%), and glomerular production of TGF-b1 (504 ±
83 pg/mL) and fibronectin (7500 ± 989 ng/mL, all P <
0.01 vs. GN and P < 0.05 vs. GN + Clopi) (Fig. 6A-D).
Enalapril limited glomerular cell proliferation more ef-
fectively than clopidogrel, but this difference did not
reach statistical significance (6.0 ± 0.9 PCNA-positive
cells/glomerular cross-section) (Fig. 5B). PAI-1 protein
expression was slightly but not significantly more reduced
by clopidogrel than by enalapril (298 ± 30 ng/mL, both
P < 0.01 vs. GN) (Fig. 6D). The animals treated with
clopidogrel showed a significant reduction in the relative
number of aneurysmatic glomeruli (5.8 ± 2.2%, P < 0.01
vs. GN) and the score indicating glomerular fibrinogen
deposition (2.5 ± 0.9%, P < 0.01 vs. GN). Enalapril
reduced these parameters as well but in a far less pro-
nounced way and not reaching statistical significance lev-
els (9.8 ± 3.8% aneurysmatic glomeruli, P = 0.07 vs.
GN, fibrinogen deposition 8.2 ± 3.1%, P = 0.18 vs. GN)
(Fig. 7). Exemplary pictures of glomerular fibrinogen de-
position in each group are shown in Figure 8.
Taken together, the results from protocol 2 show that
platelet inhibition significantly limits the fibrotic response
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Fig. 3. Indices of glomerular inducible nitric
oxide synthase (iNOS) expression (protocol 1,
injury). Shown are basal (A) and lipopolysac-
charide (LPS)-stimulated nitrite production
(B) of cultured glomeruli (2000 glomeruli per
mL and 48 hours) of animals treated with
clopidogrel (+Clopi) or enalapril (+Ena).
Glomeruli were harvested 1 day after injec-
tion of anti-thy1 antibody (GN). Normal con-
trol animals (Control) received an injection
with phosphate-buffered saline (PBS). A rep-
resentative iNOS polymerase chain reaction
(PCR) gel (C) and the densitometric analy-
sis of iNOS mRNA expression corrected for
GAPDH (D) are shown, respectively. ∗P <
0.05 and ∗∗∗P < 0.001 vs. aGN.
after induction of anti-thy1 glomerulonephritis. How-
ever, the antifibrotic efficacy of clopidogrel appears to
be lower than that of the inhibition of RAS, as shown
by direct side-by-side comparison to the ACE inhibitor
enalapril.
DISCUSSION
Localization of platelets to the site of tissue dam-
age is a key mechanism in the initiation and advance
of subsequent wound repair in many tissues and or-
gans, including skin, brain, and heart [2, 10, 11]. The
evidence for a profibrotic role of platelets in diseases
affecting the glomerular capillaries (i.e., glomeru-
lonephritis and glomerulosclerosis) has mainly been
indirect (for reviews see [15, 27]): (1) platelets and
their degranulation products have been documented in
both experimental and human glomerulopathies, such as
mesangioproliferative glomerulonephritis, membranous
glomerulonephritis, and lupus nephritis; (2) shortened bi-
ological half-life of platelets, indicating increased platelet
consumption, has been demonstrated in patients with
various glomerular diseases; and (3) platelets contain a
number of vasoactive, chemotactic, and profibrotic sub-
stances, which, when released within the glomerulus, are
likely to amplify the tissue repair process. These sub-
stances include platelet-activating factor, platelet sec-
retary products, polycationic macromolecules, platelet
factor-4, b-thromboglobulin, various growth factors, and,
important in the context of this study, high concentrations
the profibrotic cytokine TGF-b .
Using the pharmacologic platelet inhibitor clopidogrel,
the present study provides causal evidence that platelets
in part mediate overexpression of TGF-b and subsequent
matrix accumulation after the induction of experimental
anti-thy1 glomerulonephritis. Using cytotoxic antibodies
specific to platelets, a previous investigation has shown
that platelet depletion decreases early mesangial cell pro-
liferation on day 3 in a similar model of anti-thy1 glomeru-
lonephritis [20]. This finding is now expanded in a number
of important ways. Platelet inhibition (1) limits subse-
quent glomerular matrix accumulation in the later course
of the disease; (2) involves a reduction in the overproduc-
tion of the key fibrosis mediator TGF-b ; and (3) tempo-
rally localizes the beneficial effect of platelet inhibition
downstream from the initial mesangial cell injury. In ad-
dition, this study directly compares the relative contribu-
tion of platelets to glomerular matrix expansion to that of
2244 Peters et al: Platelet inhibition and glomerular matrix expansion
0
1
2
3
4
M
ac
ro
ph
ag
e 
co
un
t/g
lo
m
er
ul
ar
 s
ec
tio
n
Control GN GN
+Clopi
GN
+Ena
**
Fig. 4. Macrophage number per glomerular cross-section 1 day after
induction of acute anti-thy1 glomerulonephritis (GN) (protocol 1, in-
jury). An ED1 antibody was used for immunohistochemical detection
of macrophages. Depicted are the effects of clopidogrel (+Clopi) and
enalapril (+Ena). Normal control animals (Control) were injected with
phosphate-buffered saline (PBS). ∗∗P < 0.01 vs. aGN.
the RAS, and expands the beneficial effect of platelet in-
hibition on glomerular disease into a clinically applicable
approach.
In acute anti-thy1 glomerulonephritis, the initial tis-
sue damage is primarily directed toward mesangial cells.
However, the finding of increased glomerular thrombus
formation and fibrin deposition in day 6 animals strongly
indicates that the surrounding glomerular endothelial
cells are significantly injured as well. Damage and disrup-
tion of the endothelial cell lining and exposure to suben-
dothelial matrix components is a prerequisite for local
vascular platelet adhesion and activation [10, 11]. Activa-
tion of platelets involves a change of shape, formation of
filopedia, and release of alpha and dense granules. Some
of the released substances, especially ADP, act directly
on other platelets and cause secondary platelet aggrega-
tion, leading to fibrin and thrombus formation. In acute
anti-thy1 glomerulonephritis, the endothelial cell injury
may be caused by direct actions of inflammatory medi-
ators, but the structural consequences of mesangial cell
lysis and loss of their normal structural support of the
glomerular architecture may play a role as well. The find-
ing of endothelial damage itself is consistent with several
recent studies directly documenting a significant loss of
endothelial cells and rarefaction of the glomerular capil-
laries in early anti-thy1 nephritis [28, 29]. Here, the en-
dothelial cell damage was most prominent in glomeruli
with large capillary aneurysmal balloonings.
At present, platelet function in human disease may be
inhibited by a number of pharmacologic approaches [11,
15, 27]. We chose clopidogrel instead of the clinically
more widely used aspirin because its mode of action is
more specifically directed toward platelet inhibition. As-
pirin acts mainly via cyclooxygenase on the thrombox-
ane pathway, but may have potentially deleterious ef-
fects on the production of prostaglandins. In the kidney,
especially in chronic renal disease, prostaglandins can be
important for maintaining GFR and renal plasma flow,
thereby counterbalancing the vasoconstrictive action of
angiotensin II [15]. In addition, clinical trials in vascular
occlusive disease have suggested that clopidogrel is more
effective than aspirin [30, 31]. Inhibitors of the glycopro-
tein IIb/IIIa receptor were considered as well [11]. The
glycoprotein IIb/IIIa receptor is essential for the binding
of fibrinogen. However, because clinically effective inhi-
bition of this pathway requires continuous intravenous
administration, which restricts its applicability in renal
disease, this mode was not used in this study [11]. It may
be of interest that another way of anticoagulation therapy,
heparin, has shown beneficial effects in fibrotic renal dis-
ease as well [32]. Because heparin, which inhibits throm-
bin via activating antithrombin, ultimately decreases the
formation of fibrinogen-platelet aggregates, parts of its
beneficial action may be explained by its indirect an-
tiplatelet action.
The antifibrotic action of platelet inhibition docu-
mented here in acute glomerular wound repair may
be relevant for chronic fibrotic renal disease as well,
which in a simplistic perspective may be seen as ongo-
ing pathologic wound repair [1]. Using another clinically
introduced ADP-inhibitor, ticlopidine, Zoja et al [33] pre-
viously demonstrated a significantly slower progression in
rats with surgically reduced renal mass, as shown by pro-
teinuria, GFR, and renal matrix expansion. Given the key
role of TGF-b in tissue fibrosis in both acute and chronic
renal disease, including renal mass reduction, the findings
by Zoja et al imply that a reduction in renal TGF-b ex-
pression may be a mechanism of the antifibrotic effect of
ticlopidine. In addition, corresponding to the glomerular
endothelial damage in anti-thy1 glomerulonephritis, the
benefit of ticlopidine may be indicative of a relevant in-
jury of the peritubular endothelial cell layer in this model
of progressive interstitial fibrosis.
In the repair protocol, expression of TGF-b served
as the main measure of therapeutic efficacy for clopi-
dogrel and enalapril. Thereby, this study contributes to
a recent study series comparing and contrasting antifi-
brotic therapies in anti-thy1 glomerulonephritis, using
the same disease model, rat strain, anti-thy1 antibody,
harvest times, and measures of fibrosis. This series so
far covers ACE inhibition, angiotensin type-1 receptor
Peters et al: Platelet inhibition and glomerular matrix expansion 2245
Control GN GN
+Clopi
GN
+Ena
Control GN GN
+Clopi
GN
+Ena
40
0
80
120
160
Al
bu
m
in
ur
ia
, m
g/
d
*
A
0
3
6
9
12
PC
NA
 
po
sit
ive
 c
el
ls/
gl
om
er
ul
ar
 s
ec
tio
n
**
*
B
Fig. 5. Urinary albumin excretion (A) and
proliferating cell nuclear antigen (PCNA)-
positive cells per glomerular section (B) 6 days
after induction of acute anti-thy1 glomeru-
lonephritis (GN) (protocol 2, repair). Treat-
ment with clopidogrel (+Clopi) and enalapril
(+Ena) was started 24 hours after disease in-
duction. Urine was collected for 24 hours us-
ing metabolic cages. PCNA staining was used
as a marker for proliferating cells. ∗P < 0.05
and ∗∗P < 0.01 vs. aGN.
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Fig. 6. Markers of glomerular matrix expan-
sion 6 days after induction of acute anti-
thy1 glomerulonephritis (GN) (protocol 2, re-
pair). Shown are the glomerular matrix accu-
mulation (A) and glomerular production of
transforming growth factor (TGF)-b1 (B), fi-
bronectin (C), and plasminogen activator in-
hibitor (PAI)-1 (D). Control animals received
phosphate-buffered saline (PBS) (Control).
Treatment with clopidogrel (+Clopi) and
enalapril (+Ena) was started 24 hours after
disease induction. Glomeruli were harvested
from individual animals and cultured at a den-
sity of 2000 per mL for 48 hours. ∗P < 0.05 and
∗∗P < 0.01 vs. aGN, #P < 0.05 vs. aGN+Clopi.
antagonisms, adrenergic b-receptor blockade, low-
protein diet, and L-arginine supplementation [16, 23,
24, 34]. In the present study, direct side-by-side com-
parison showed that ACE inhibition with enalapril
reduced TGF-b1 overexpression significantly more ef-
fectively than clopidogrel. Similar results were observed
with regard to proteinuria, actual glomerular matrix ex-
pansion, and fibronectin expression. Because both drugs
were given in maximally effective high doses [16, 18], and
as far as pharmacologically feasible, our results in anti-
thy1 glomerulonephritis imply that the relative impact of
platelets on TGF-b1 overexpression is not as great as that
of the RAS.
In human renal disease, the situation on platelet in-
hibition is characterized by a general lack of controlled
clinical trials with a sufficient number of patients. As
early as 1972, benefits from antiplatelet drugs were re-
ported by Kincaid-Smith in a small group of patients
with membranoproliferative glomerulonephritis treated
with cyclophosphamide, the anticoagulant warfarin, and
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Fig. 7. Markers of glomerular thrombosis
6 days after induction of acute anti-thy1
glomerulonephritis (GN) (protocol 2, repair).
Shown are the histologic scores for glomeru-
lar aneurysm formation (A) and fibrinogen
depositions (B). Treatment with clopidogrel
(+Clopi) and enalapril (+Ena) was started
24 hours after disease induction. ∗∗P < 0.01
vs. aGN.
Fig. 8. Glomerular fibrinogen deposition 6 days after induction of acute anti-thy1 glomerulonephritis (GN) (protocol 2, repair). Characteristic
photographs show tissue from normal control animals (A), anti-thy1 animals without (B) or with clopidogrel (C) or enalapril (D) treatment.
Immunohistochemistry was performed using a primary rabbit anti-fibrinogen and a secondary goat anti-rabbit antibody coupled with the EnvisionTM
staining system.
dipyridamonle [35]. Although a few small studies using
different antiplatelet and anticoagulant strategies were
able to confirm the improvement, others showed no sig-
nificant benefit [15]. With regard to ADP antagonism, a
small study in 11 patients with chronic glomerulopathies
may be of interest, in which a two-year course of ticlo-
pidine reduced proteinuria significantly [15]. The antifi-
brotic benefit of clopidogrel, now demonstrated in acute
anti-thy1 glomerulonephritis, underscores the need for
control trials. In addition, as a result of the relatively
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smaller antifibrotic potential of clopidogrel, our data sug-
gest that larger patient numbers will be needed than in
the ACE inhibitor trials.
In this study, actions on mesangial cell injury in anti-
thy1 glomerulonephritis were analyzed separately be-
cause it has been shown that positive or negative changes
in the initial mesangial cell lysis are reflected in oppos-
ing changes in the later matrix expansion phase [5, 19].
In the injury protocol, clopidogrel did not affect the ini-
tial injury phase; however, enalapril reduced the number
of lysed mesangial cells significantly. This benefit went in
tandem with reduced iNOS mRNA expression and NO
production. Given the critical role of NO for anti-thy1
antibody-induced mesangial cell lysis [17], the data sug-
gest that a reduction in inducible NO production was the
mechanism. Part of the decreased glomerular iNOS ex-
pression can be explained by the reduced macrophage in-
filtration, which is an important source of iNOS enzyme
in this model. Similar to this study, an anti-inflammatory
action of ACE inhibition has previously been demon-
strated in chronic, iNOS-mediated lupus nephritis of
MRL/lpr mouse [36] [abstract; Perez de Lema et al, J
Am Soc Nephrol 13:174A, 2002]. Together, these studies
are consistent with the concept that angiotensin II, in-
dependent of blood pressure, acts as a proinflammatory
molecule capable of directly regulating the expressions of
nuclear transcription factor-kappab , chemokines (MCP-
1 and RANTES), and iNOS [37, 38].
CONCLUSION
The present study shows that platelets play a signif-
icant role in the sequence from mesangial cell damage
to TGF-b overexpression and matrix expansion in acute
anti-thy1 glomerulonephritis. Furthermore, the compar-
ison of platelet and ACE inhibition directly side-by-side
suggests that the contribution of platelets to TGF-b over-
expression is not as great as that of the RAS in this
glomerular model of acute wound repair.
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